Corporate & Investor Presentation slide image

Corporate & Investor Presentation

Capital allocation $ in millions 3Q21 Cash and cash equivalents $231 Debt $731 Net debt $500 Free cash flow $170 Unused borrowing capacity $1,530 NOTE: Values may not calculate due to rounding During 3Q21 $56M invested in R&D (7% of revenue) Paid $57M in dividends to shareholders 30 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Capital Allocation Organic business growth Free cash flow Higher priority Dividends Share buybacks M&A Lower priority ResMed
View entire presentation